2024
Sex differences in comorbid pain and opioid use disorder: A scoping review
DeVito E, Ameral V, Sofuoglu M. Sex differences in comorbid pain and opioid use disorder: A scoping review. British Journal Of Clinical Pharmacology 2024, 90: 3067-3083. PMID: 39168150, DOI: 10.1111/bcp.16218.Peer-Reviewed Original ResearchOpioid use disorderChronic painTreatment of opioid use disorderChronic opioid usePost hoc analysisPersistent painClinical courseOpioid useComorbid painSex/gender differencesOpioid misuseOpioidPainUse disorderHighest prevalencePost-hocOutcome variablesDisordersTreatmentHuman subjectsBiological underpinningsPsychosocial factorsTreatment effectsSex differencesSexEXAMINING RACIAL DIFFERENCES IN SMOKING-RELATED OUTCOMES IN HUMANS DURING EARLY ABSTINENCE AND AFTER INTRAVENOUS NICOTINE INFUSION
Schwartz E, Palmisano A, Gueorguieva R, DeVito E, Sofuoglu M. EXAMINING RACIAL DIFFERENCES IN SMOKING-RELATED OUTCOMES IN HUMANS DURING EARLY ABSTINENCE AND AFTER INTRAVENOUS NICOTINE INFUSION. Drug And Alcohol Dependence 2024, 260: 110027. DOI: 10.1016/j.drugalcdep.2023.110027.Peer-Reviewed Original Research
2023
Threshold for the Pleasurable Effects of Nicotine Are Lower Than Its Reinforcing Effects During Self-Administration
MacLean RR, Eid T, Parida S, Gueorguieva R, DeVito EE, Sofuoglu M. Threshold for the Pleasurable Effects of Nicotine Are Lower Than Its Reinforcing Effects During Self-Administration. Experimental And Clinical Psychopharmacology 2023, 31: 37-45. PMID: 35254839, PMCID: PMC9448824, DOI: 10.1037/pha0000556.Peer-Reviewed Original ResearchConceptsNicotine metabolite ratioDose of nicotineNicotine reinforcementSubjective effectsDiscriminative stimulus effectsHeart rate increaseDoses of nicotineSelf-administration procedureSubjective positive effectsDaily smokersBaseline cravingIntravenous nicotineOvernight abstinenceCigarette cravingDrug effectsMetabolite ratiosStimulus effectsSecondary analysisPlaceboSelf-AdministrationNicotine choiceTobacco productsNicotinePleasurable effectsYoung adultsExamining racial differences in smoking outcomes among smokers enrolled in an intravenous nicotine infusion study
Schwartz E, Palmisano A, Gueorguieva R, DeVito E, Sofuoglu M. Examining racial differences in smoking outcomes among smokers enrolled in an intravenous nicotine infusion study. Addictive Behaviors 2023, 140: 107615. PMID: 36640662, PMCID: PMC9911383, DOI: 10.1016/j.addbeh.2023.107615.Peer-Reviewed Original ResearchConceptsSmoking-related illnessesNegative drug effectsNicotine clearanceOvernight abstinenceNicotine infusionDrug effectsMentholated cigarettesWhite individualsBlack individualsAcute pharmacologic effectsSmoking-related morbiditySmoking-related diseasesAdministration of nicotineSmoking-related outcomesSubjective drug effectsShort-term abstinenceLower ratesTrend level differenceLarge racial disparitiesNicotine administrationNicotine dosesTrend-level significancePharmacologic effectsTreatment strategiesOutcome measures
2022
Catechol-O-Methyltransferase Effects on Smoking: a Review and Proof of Concept of Sex-Sensitive Effects
DeVito E, Sofuoglu M. Catechol-O-Methyltransferase Effects on Smoking: a Review and Proof of Concept of Sex-Sensitive Effects. Current Behavioral Neuroscience Reports 2022, 9: 113-123. PMID: 36644316, PMCID: PMC9838826, DOI: 10.1007/s40473-022-00251-2.Peer-Reviewed Original ResearchSmoking behaviorPreliminary dataHuman laboratory studiesCigarette smoking behaviorShort-term abstinenceNicotine administrationSmoking cessationTreatment optionsWithdrawal symptomsCessation outcomesPharmacogenetic effectsOvernight abstinenceMet carriersSmoking urgesActivity genotypeReviewThis articleSymptomsCOMT geneSex differencesAbstinenceFunctional variantsSmokingCigarettesAdministrationIndividualsDevelopment of pulsed intravenous nicotine infusions as a model for inhaled nicotine in humans
De Aquino JP, DeVito EE, Xie C, Meyerovich J, Parida S, Gueorguieva R, Sofuoglu M. Development of pulsed intravenous nicotine infusions as a model for inhaled nicotine in humans. Psychopharmacology 2022, 239: 2809-2818. PMID: 35554617, DOI: 10.1007/s00213-022-06162-0.Peer-Reviewed Original ResearchPlasma Menthol Glucuronide as a Biomarker for the Behavioral Effects of Menthol and Nicotine in Humans
Gueorguieva R, Schwartz EKC, MacLean RR, DeVito EE, Eid T, Wu R, O’Malley S, Sofuoglu M. Plasma Menthol Glucuronide as a Biomarker for the Behavioral Effects of Menthol and Nicotine in Humans. Frontiers In Pharmacology 2022, 13: 844824. PMID: 35431934, PMCID: PMC9009207, DOI: 10.3389/fphar.2022.844824.Peer-Reviewed Original ResearchSubjective drug effectsPlasma Mg concentrationHeart rateDrug effectsIntravenous deliveryNon-menthol cigarette smokersPlacebo-controlled studyTest sessionsCigarette smokersMenthol smokersAcute effectsIntravenous nicotineGlucuronide concentrationsMAIN OUTCOMENicotine infusionMenthol glucuronideSecondary analysisPlasma MgE-cigarettesBehavioral effectsMenthol exposureNicotineSmokersPhysiological effectsE-liquidsModafinil does not reduce cocaine use in methadone-maintained individuals
DeVito EE, Poling J, Babuscio T, Nich C, Carroll KM, Sofuoglu M. Modafinil does not reduce cocaine use in methadone-maintained individuals. Drug And Alcohol Dependence Reports 2022, 2: 100032. PMID: 36310662, PMCID: PMC9615926, DOI: 10.1016/j.dadr.2022.100032.Peer-Reviewed Original ResearchCocaine use disorderCocaine use outcomesOpioid useCognitive behavioral therapyContingency managementCocaine dependenceCognitive functionMethadone-maintained individualsUse outcomesEfficacy of modafinilSelf-reported abstinenceTreatment of CUDStimulant-like effectsPlatform treatmentPercentage of urinesPercent of daysDual opioidModafinil treatmentUse disordersPotential efficacyCocaine useModafinilPlaceboMinimal reportsBehavioral therapyImpact of delivery rate on the acute response to intravenous nicotine: A human laboratory study with implications for regulatory science
De Aquino JP, MacLean RR, Gueorguieva R, DeVito EE, Eid T, Sofuoglu M. Impact of delivery rate on the acute response to intravenous nicotine: A human laboratory study with implications for regulatory science. Addiction Biology 2022, 27: e13161. PMID: 35229960, PMCID: PMC8903077, DOI: 10.1111/adb.13161.Peer-Reviewed Original ResearchConceptsAbuse potentialPositive subjective drug effectsSubjective drug effectsHuman laboratory studiesPositive subjective effectsAttention functionSmoking urgesOvernight abstinencePotential therapeutic effectsEffects of nicotineHeart rate increaseDelivery rateDependent smokersExperimental sessionsSubjective effectsNicotine dependenceIntravenous nicotineBlood pressureSaline infusionAcute effectsTherapeutic effectHeart rateDrug effectsAcute responseCrossover design
2021
Threshold dose for intravenous nicotine self-administration in young adult non-dependent smokers
MacLean RR, DeVito EE, Eid T, Parida S, Gueorguieva R, Sofuoglu M. Threshold dose for intravenous nicotine self-administration in young adult non-dependent smokers. Psychopharmacology 2021, 238: 2083-2090. PMID: 33796907, PMCID: PMC8715498, DOI: 10.1007/s00213-021-05833-8.Peer-Reviewed Original ResearchConceptsDose of nicotineNicotine reinforcementHigh doseSubjective effectsHuman laboratory studiesYoung adult smokersNicotine self-administration modelNon-dependent smokersOvernight nicotine abstinenceEffects modelSelf-administration modelSelf-administration procedureNicotine doseAdult smokersMethodsYoung adultsObjectivesThe current studyNicotine abstinenceNicotine addictionHigh dosesLow dosesPlaceboThreshold doseReinforcement thresholdTobacco productsDose
2019
Randomized placebo-controlled trial of galantamine in individuals with cocaine use disorder
DeVito EE, Carroll KM, Babuscio T, Nich C, Sofuoglu M. Randomized placebo-controlled trial of galantamine in individuals with cocaine use disorder. Journal Of Substance Use And Addiction Treatment 2019, 107: 29-37. PMID: 31757262, PMCID: PMC6918721, DOI: 10.1016/j.jsat.2019.08.009.Peer-Reviewed Original ResearchConceptsCocaine use disorderSignificant treatment group differencesUse disordersEfficacy of galantamineTreatment-seeking cocaine usersCurrent cocaine use disordersGroup differencesCocaine use outcomesSample of individualsTreatment group differencesComorbid opioid use disorderMethadone-maintained individualsMemory capacityAbstinent individualsCocaine useCognitive improvementCognitive outcomesCocaine use reductionCognitive functionUse outcomesCocaine usersGalantamine groupIndividualsDisordersInitial promiseDouble‐Blind Placebo‐Controlled Trial of Galantamine for Methadone‐Maintained Individuals With Cocaine Use Disorder: Secondary Analysis of Effects on Illicit Opioid Use
Carroll KM, DeVito EE, Yip SW, Nich C, Sofuoglu M. Double‐Blind Placebo‐Controlled Trial of Galantamine for Methadone‐Maintained Individuals With Cocaine Use Disorder: Secondary Analysis of Effects on Illicit Opioid Use. American Journal On Addictions 2019, 28: 238-245. PMID: 31165574, PMCID: PMC9078084, DOI: 10.1111/ajad.12904.Peer-Reviewed Original ResearchConceptsMethadone-maintained individualsOpioid useSecondary analysisMultiple drugsConcurrent cocaine dependenceTrial of galantaminePlacebo-controlled trialDouble-blind placeboIllicit opioid useRandomized clinical trialsCocaine use disorderGalantamine's effectFuture trialsClinical trialsUrine specimenUrine specimensUse disordersOpioidsCholinesterase inhibitorsMaintenance settingCocaine useCocaine dependencePlaceboConcurrent useGalantamine
2018
Pharmacological and Behavioral Treatment of Opioid Use Disorder
Sofuoglu M, DeVito E, Carroll K. Pharmacological and Behavioral Treatment of Opioid Use Disorder. Psychiatric Research And Clinical Practice 2018, 1: 4-15. PMCID: PMC9175946, DOI: 10.1176/appi.prcp.20180006.Peer-Reviewed Original ResearchOpioid use disorderMedication-assisted treatmentSubstance use conditionsBehavioral treatmentTreatment retentionUse disordersBehavioral interventionsOpioid withdrawal symptomsFirst-line treatmentMechanism of actionOUD treatmentComorbid conditionsMedication complianceWithdrawal symptomsClinical overviewClinical guidelinesOpioid receptorsAdrenergic agonistsNonsystematic reviewDrug AdministrationKey pharmacologicalBehavioral therapyTreatment effectivenessComplex needsTreatmentThe Cholinergic System as a Treatment Target for Opioid Use Disorder
Jensen KP, DeVito EE, Yip S, Carroll KM, Sofuoglu M. The Cholinergic System as a Treatment Target for Opioid Use Disorder. CNS Drugs 2018, 32: 981-996. PMID: 30259415, PMCID: PMC6314885, DOI: 10.1007/s40263-018-0572-y.Peer-Reviewed Original ResearchConceptsCholinergic systemUse disordersTreatment targetsOpioid use disorder epidemicCentral nervous system functionTreatment of OUDEffects of acetylcholineOpioid use disorderTobacco use disorderNervous system functionOpioid medicationsDegrade acetylcholineCurrent treatmentOpioid overdosesPreclinical studiesMedicationsAcetylcholineCholinesterase inhibitorsAlzheimer's diseaseNew treatmentsAccidental deathGlobal healthTreatmentOUDDisease
2015
Intravenous Nicotine Self-Administration in Smokers: Dose–Response Function and Sex Differences
Jensen KP, DeVito EE, Valentine G, Gueorguieva R, Sofuoglu M. Intravenous Nicotine Self-Administration in Smokers: Dose–Response Function and Sex Differences. Neuropsychopharmacology 2015, 41: 2034-2040. PMID: 26717881, PMCID: PMC4908640, DOI: 10.1038/npp.2015.373.Peer-Reviewed Original ResearchConceptsBlood pressureHeart rateFemale smokersRandomized double-blind crossover designDouble-blind crossover designSubjective effectsTobacco-dependent subjectsSex differencesDiastolic blood pressureIntravenous Nicotine Self-AdministrationSelf-administration ratesNicotine Self-AdministrationDose-response functionNicotine dosesNicotine doseTobacco dependenceIntravenous nicotineCrossover designSelf-AdministrationReinforcement thresholdSmokersInfusionNicotineForced-choice trialsAversive responses
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply